Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000724332 | SCV000225427 | uncertain significance | not provided | 2014-11-18 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000724332 | SCV000491946 | uncertain significance | not provided | 2018-05-11 | criteria provided, single submitter | clinical testing | A variant of uncertain significance has been identified in the BSCL2 gene. The R392H variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to our knowledge. This variant is observed in 32/30780 (0.1%) alleles from individuals of South Asian background in large population cohorts (Lek et al., 2016). The R392H variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. However, in-silico analyses, including protein predictors and evolutionary conservation, support a deleterious effect. Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic variant or a rare benign variant. |
Personalized Diabetes Medicine Program, |
RCV000445495 | SCV000537081 | uncertain significance | Monogenic diabetes | 2015-12-04 | criteria provided, single submitter | research | ACMG Criteria: PP3 |
Labcorp Genetics |
RCV001086117 | SCV000775905 | likely benign | Charcot-Marie-Tooth disease type 2 | 2025-01-07 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000724332 | SCV001475546 | uncertain significance | not provided | 2020-03-11 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV001847805 | SCV002106250 | uncertain significance | Hereditary spastic paraplegia | 2021-09-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002326952 | SCV002629234 | likely benign | Inborn genetic diseases | 2022-05-10 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Revvity Omics, |
RCV000724332 | SCV003830190 | uncertain significance | not provided | 2019-06-04 | criteria provided, single submitter | clinical testing | |
Clinical Genomics, |
RCV003884374 | SCV004698137 | uncertain risk allele | Congenital generalized lipodystrophy type 2 | criteria provided, single submitter | research | Potent mutations in BSCL2 gene are associated with Congenital generalized lipodystrophy, type 2, which can present with insulin resistance, fatty liver and diabetes.However, the role of this particular variant rs149466797 of Congenital Generalized Lipodystrophy type 2 remains uncertain | |
Mayo Clinic Laboratories, |
RCV000724332 | SCV005412346 | uncertain significance | not provided | 2024-03-22 | criteria provided, single submitter | clinical testing |